Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

BUY
$0.64 - $3.15 $53,160 - $261,648
83,063 New
83,063 $58,000
Q2 2022

Aug 08, 2022

SELL
$3.17 - $6.17 $70,713 - $137,634
-22,307 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$4.16 - $13.72 $46,159 - $152,237
11,096 Added 98.97%
22,307 $120,000
Q4 2021

Feb 14, 2022

SELL
$10.83 - $18.41 $288,955 - $491,197
-26,681 Reduced 70.41%
11,211 $151,000
Q3 2021

Nov 15, 2021

BUY
$13.07 - $18.84 $495,248 - $713,885
37,892 New
37,892 $681,000
Q1 2021

May 17, 2021

SELL
$16.56 - $25.46 $237,735 - $365,503
-14,356 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$15.77 - $19.03 $84,085 - $101,467
5,332 Added 59.09%
14,356 $244,000
Q1 2020

May 15, 2020

BUY
$14.47 - $27.96 $120,650 - $233,130
8,338 Added 1215.45%
9,024 $161,000
Q4 2019

Feb 14, 2020

SELL
$15.87 - $23.12 $52,894 - $77,058
-3,333 Reduced 82.93%
686 $15,000
Q2 2019

Aug 14, 2019

BUY
$31.0 - $36.3 $87,451 - $102,402
2,821 Added 235.48%
4,019 $143,000
Q1 2019

May 15, 2019

SELL
$31.58 - $46.35 $74,844 - $109,849
-2,370 Reduced 66.42%
1,198 $40,000
Q4 2018

Feb 14, 2019

BUY
$30.43 - $56.65 $44,488 - $82,822
1,462 Added 69.42%
3,568 $117,000
Q3 2018

Nov 14, 2018

BUY
$46.46 - $68.49 $59,097 - $87,119
1,272 Added 152.52%
2,106 $128,000
Q2 2018

Aug 14, 2018

SELL
$46.25 - $104.45 $895,076 - $2.02 Million
-19,353 Reduced 95.87%
834 $41,000
Q4 2017

Feb 14, 2018

BUY
$23.02 - $60.5 $294,080 - $772,887
12,775 Added 172.36%
20,187 $1.21 Million
Q3 2017

Nov 14, 2017

BUY
$17.79 - $24.0 $95,603 - $128,976
5,374 Added 263.69%
7,412 $178,000
Q2 2017

Aug 14, 2017

BUY
N/A
2,038
2,038 $40,000

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $201M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Walleye Trading LLC Portfolio

Follow Walleye Trading LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Trading LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Trading LLC with notifications on news.